ESMO 2026持续更新

FOURLIGHT-1

26 篇报道2 个报道来源8 小时前更新

先了解这件事

事件综述

2026年10月25日，中文产业新闻报道，OncoAlert 4Sight有三项研究摘要拟在2026 ESMO展示，主题集中于HR+/HER2−晚期乳腺癌患者在CDK4/6抑制剂治疗后出现进展时的后续治疗。三项摘要分别涉及atirmociclib、abemaciclib和giredestrant联合方案。报道未披露具体研究设计、样本规模、疗效或安全性结果，也未给出研究结论；目前可确认的进展是上述三项摘要将在ESMO聚焦该类患者的进展后治疗策略。

由模型根据报道生成 · 3 小时前更新

最新进展10月26日 06:21

ESMO 2026三项摘要聚焦CDK4/6抑制剂治疗后进展的乳腺癌后续治疗。

报道时间线

沿着报道，了解事件的不同侧面。

10月26日

06:21
ESMO 2026 现场信号
New findings from the FOURLIGHT-1 trial presented at #ESMO26 suggest atirmociclib plus Faslodex may help people with HR+, HER2-negative metastatic breast cancer live longer without

10月25日

20:00
中文产业新闻精选
2026 ESMO三项摘要聚焦CDK4/6抑制剂治疗后进展的晚期乳腺癌后续治疗
2026 ESMO三项摘要聚焦HR+/HER2−晚期乳腺癌在CDK4/6抑制剂治疗后进展的后续治疗，分别涉及atirmociclib、abemaciclib和giredestrant联合方案。
06:51
ESMO 2026 现场信号
FOURLIGHT-1 at #ESMO26: atirmociclib + fulvestrant improved PFS vs. investigator’s choice in HR+/HER2− mBC after a CDK4/6 inhibitor (median 9.4 vs. 6.6 mo; HR 0.60). Antonio Giorda
05:04
ESMO 2026 现场信号
FOURLIGHT-1: HR+/HER2− breast cancer after CDK4/6i.
03:55
ESMO 2026 现场信号
#ScienceLink #Madrid2026 #ESMO26 #FOURLIGHT1 #atirmociclib
00:00
ESMO 2026 现场信号
🔴 Live from #ESMO2026

10月24日

17:50
ESMO 2026 现场信号
#ESMO26 🇪🇸 | FOURLIGHT-1 :
16:15
ESMO 2026 现场信号
FourLight-1 #ESMO26
15:52
ESMO 2026 现场信号
🔥 FOURLIGHT-1 demonstrates atirmociclib efficacy post-CDK4/6i
15:51
ESMO 2026 现场信号
Can selective CDK4 inhibition overcome resistance to CDK4/6 inhibitors?
15:37
ESMO 2026 现场信号
Am I the only one at #ESMO26 who thinks FOURLIGHT-1 lacks an appropriate comparator? Why not use everolimus plus endocrine therapy (investigator’s choice) as the control arm, as in
15:27
ESMO 2026 现场信号
After CDK4/6i in HR+ MBC, the control arm is the story at #ESMO2026.
15:24
ESMO 2026 现场信号
Great to see my longtime friend @antgiorda present FOURLIGHT-1 at #ESMO26: atirmociclib + fulvestrant improved PFS vs investigator's choice after prior CDK4/6 (9.4 vs 6.6 mo, HR 0.
15:15
ESMO 2026 现场信号
🔹CDK4 selective inh Atirmociclib + fulvestrant improved mPFS vs investigator’s choice post-CDK4/6i in the FourLight-1 ph2 trial
15:09
ESMO 2026 现场信号
📌 Proffered paper 2: Breast cancer, early and advanced stage
15:07
ESMO 2026 现场信号
FourLight-1 presented by @antgiorda at #ESMO26
15:06
ESMO 2026 现场信号
HR+HER2- MBCへのCDK4/6i後、CDK4阻害薬のatirmociclib+FULのPhase 2 FOURLIGHT-1試験。
15:06
ESMO 2026 现场信号
At #ESMO26 Proffered Paper 2️⃣ on #breastcancer
15:06
ESMO 2026 现场信号
FOURLIGHT-1
15:03
ESMO 2026 现场信号
#ESMO26 | FOURLIGHT-1
14:55
ESMO 2026 现场信号
#BreastCancer research at #ESMO26: Antonio Gioradano, MD, of @DanaFarber presents efficacy and safety of atirmociclib + fulvestrant in HR+/HER2- advanced breast cancer after progre
14:46
ESMO 2026 现场信号
📢 #ESMO26 concomitant paper - Atirmociclib and fulvestrant for patients with HR+/HER2– advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhib

10月23日

17:15
ESMO 2026 现场信号
🧬 After progression on a CDK4/6 inhibitor, is it time to rethink whether the class can still work?

10月22日

17:26
ESMO 2026 现场信号
Looking forward to this one at #ESMO26 👀
00:49
ESMO 2026 现场信号
@ChandrakanthMv's seven-point breakdown makes FOURLIGHT-1 easy to teach. The nuance for fellows: atirmociclib is CDK4-selective, and sparing CDK6 is meant to ease the neutropenia t

10月21日

22:01
ESMO 2026 现场信号
OncoAlert 4Sight Abstracts to be Presented at #ESMO26

本事件热度走势

当前热度 73·可比范围峰值 157（10月24日 18:00）·近 24 小时可比范围变化 -38%·当前参与者 25

参与者计数25

热度走势

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。